VEGFA and glioblastoma: Regorafenib, a VEGF inhibitor with affinity for multiple VEGF receptors and PDGF receptors, did significantly improve PFS and OS in patients with rGBM compared to lomustine in an initial study (NTC02926222), but subsequent study as part of the GBM Adaptive Global Initiative Learning Environment (AGILE) trial did not demonstrate OS benefit [123,124].